¾«Æ·¹ú²úÒ»Çø¶þÇøÌÒÉ«

One of the ways that cancer cells hide from the body’s immune system is by forming a thin surface barrier called the glycocalyx. In a new study, researchers examined the material properties of this barrier with unprecedented resolution, revealing information that could help improve current cell-based cancer immunotherapies.

Sangwoo Park, Cornell University

Researchers engineered immune cells (NK-92) to anchor glycocalyx-editing (GE) enzymes on the surface. The modified immune cells were able to break through the glycocalyx armor of cancer cells.

Cancer cells often form the glycocalyx with high levels of cell-surface mucins, which are thought to help protect the cancer cell from immune cell attack. However, a physical understanding of this barrier has remained limited, especially as it relates to cell-based cancer immunotherapies, which involve removing immune cells from a patient, modifying them to seek and destroy cancer, and then putting them back into the patient’s body.

“We found that changes in the thickness of the barrier that were as small as 10 nanometers could affect the antitumor activity of our immune cells or the engineered cells used for immunotherapy,” said Sangwoo Park, a graduate student in Matthew Paszek’s Lab at Cornell University in Ithaca, New York. “We used this information to engineer immune cells that can get through the glycocalyx, and we hope this approach could be used to enhance current cell-based immunotherapies.”
Park will present the findings at , the annual meeting of the ¾«Æ·¹ú²úÒ»Çø¶þÇøÌÒÉ«, March 25–28 in Seattle.

“Our lab has advanced a powerful strategy called scanning angle interference microscopy (SAIM) for measuring the nanoscale dimensions of the cancer cell glycocalyx,” said Park. “This imaging technique allows us to understand the structural relationship of cancer-associated mucins to the biophysical properties of the glycocalyx.”

The researchers generated a cellular model to precisely control the cell-surface mucin expression to mimic the cancer cell glycocalyx. They then combined SAIM with genetic approaches to study how the surface density, glycosylation and crosslinking of cancer-associated mucins affect the thickness of the barrier at the nanoscale. They also analyzed how the glycocalyx thickness affected a cell’s resistance to attack by immune cells.

The study revealed that the thickness of cancer cells' glycocalyx is one of the major parameters determining immune cell evasion and that engineered immune cells worked better if the glycocalyx was thinner.

Based on this knowledge, the researchers engineered immune cells with special enzymes on their surface to allow them to attach to and interact with the glycocalyx. Experiments performed at the cellular level showed that these immune cells were able to overcome the glycocalyx armor of cancer cells.

Next, the researchers plan to determine whether these findings can be replicated in the laboratory and, eventually, in clinical trials.

Sangwoo Park will present this research during the Regulatory Glycosylation Spotlight Session from 2–3 p.m. PDT on Sunday, March 26, in Room 608 of the Seattle Convention Center (). Contact the media team for more information or to obtain a free press pass to attend the meeting.